Skip to main content
SpringerLink
Log in

Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares

  • Adis Drug Clinical Q&A
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Canakinumab (Ilaris®), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a targeted population of patients in whom treatment options are limited. Relative to on-demand treatment with intramuscular triamcinolone acetonide 40 mg, on-demand treatment with subcutaneous canakinumab 150 mg significantly relieved the pain and inflammation of a new gout flare, and reduced the risk of new flares in patients with acute gouty arthritis flares in whom standard treatment with non-steroidal anti-inflammatories and/or colchicine was inappropriate. Canakinumab has an acceptable tolerability profile in this difficult-to-treat population. The increased risk of infections and neutropenia associated with canakinumab treatment can be minimized by following the recommended precautions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs. 2011;71(11):1413–9.

    Article  PubMed  CAS  Google Scholar 

  2. Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39–49.

    PubMed  CAS  Google Scholar 

  3. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013;19(1):19–29.

    PubMed  Google Scholar 

  4. Stamp LK, Jordan S. The challenges of gout management in the elderly. Drug Aging. 2011;28(8):591–603.

    Article  CAS  Google Scholar 

  5. Hamburger M, Baraf HS, Adamson TC 3rd, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 Suppl 1):3–36.

    Article  PubMed  Google Scholar 

  6. Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155–65.

    Article  PubMed  CAS  Google Scholar 

  7. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46.

    Article  CAS  Google Scholar 

  8. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–24.

    Article  PubMed  CAS  Google Scholar 

  9. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447–61.

    Article  CAS  Google Scholar 

  10. Ilaris (canakinumab) 150 mg powder for solution for injection: summary of product characteristics. London: European Medicines Agency; 2013.

  11. Curran MP. Canakinumab in patients with cryopyrin-associated periodic syndromes. Biodrugs. 2012;26(1):53–9.

    Article  PubMed  CAS  Google Scholar 

  12. Church LD, McDermott MF. Canakinumab, a fully human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11(1):81–9.

    PubMed  CAS  Google Scholar 

  13. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1–18.

    Article  PubMed  CAS  Google Scholar 

  14. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R6.

    Article  Google Scholar 

  15. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48.

    Article  PubMed  CAS  Google Scholar 

  16. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064–76.

    Article  PubMed  CAS  Google Scholar 

  17. Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13(2):R53.

    Article  PubMed  CAS  Google Scholar 

  18. Doherty M, Bardin T, Pascual E. International survey on the diagnosis and management of gout. Ann Rheum Dis. 2007;66(12):1685–6.

    Article  PubMed  CAS  Google Scholar 

  19. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765–70.

    Article  PubMed  Google Scholar 

  20. Edwards NL. Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep. 2011;13(2):154–9.

    Article  PubMed  Google Scholar 

  21. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the review process, the manufacturer of the agent under review were offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Additional information

The manuscript was reviewed by: R.E. Alten, Department of Internal Medicine, Rheumatology, Schlosspark-Klinik, Charité University Medicine, Berlin, Germany; K.K. Viktal, Diakonhjemmet Hospital Pharmacy, Oslo, Norway.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A. Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares. BioDrugs 27, 401–406 (2013). https://doi.org/10.1007/s40259-013-0037-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-013-0037-2

Keywords

Search

Navigation